EP3283882

MERCK SHARP & DOHME CORP.
Application Number
EP16780526A
Filing Date
Apr 12, 2016
Status
Patent Maintained As Amended
Sep 13, 2024
Grant Date
Oct 16, 2024
External Links
Slate, Register

Biblio Summary

The patent EP3283882B2 was granted on Oct 16, 2024 by Merck Sharp & Dohme Corp. The patent is currently Patent Maintained As Amended.

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SYMBIOSIS IP LIMITEDSep 15, 2021ADMISSIBLE

The table below shows the patents of Merck Sharp & Dohme Corp. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP1841493Applicator For Inserting An ImplantMay 29, 20241
EP3265122Combination Of A Pd-1 Antagonist And Eribulin For Treating CancerMay 4, 20224
EP2981821Immunohistochemical Assay For Detecting Expression Of Programmed Death Ligand 1 (Pd-L1) In Tumor TissueNov 3, 20211